Progenics other research news

The Tarrytown, N.Y., company received an $80,000 Phase I SBIR grant from the NIH's National Institute of Allergy and Infectious Diseases to fund the development of ProScan-A, a diagnostic imaging agent for HIV.

ProScan-A uses Progenics' HIV Universal Neutralizing Antibody (UNAb) molecule linked to a radioisotope. A ProScan-A image is designed to monitor the distribution and burden of HIV throughout the body for use in patient management, particularly during the asymptomatic period of infection. ...